Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis

The Oncologist
Lova SunZachariah DeFilipp

Abstract

High-dose chemotherapy and autologous stem cell transplantation (ASCT) can offer durable remission in many patients with relapsed or high-risk lymphoma. However, elderly patients are often not considered ASCT candidates based on age alone. A retrospective analysis of patients ≥70 years of age with a diagnosis of Hodgkin or non-Hodgkin lymphoma receiving ASCT between 2000 and 2016 at two partner institutions was performed. Clinical data were extracted from institutional databases and individual medical records. Multivariate analysis was performed to examine the association of clinical variables with transplant outcomes. One hundred seven patients were identified. Median age at transplant was 72 years (range, 70-79). The most common lymphoma subtype was diffuse large B-cell (n = 63, 59%). Median time to neutrophil and platelet engraftment were 10 and 12 days, respectively. With a median follow-up for survivors of 20 months following ASCT (range, 6 months to 13.1 years), estimates for 2-year progression-free survival and overall survival were 58% (95% confidence interval [CI], 48%-67%) and 65% (95% CI, 55%-74%), respectively. Two-year estimate for relapse was 34% (95% CI, 25%-44%) and nonrelapse mortality (NRM) was 7% (95% CI, 3%-...Continue Reading

References

Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C R Kusnierz-GlazG D Long
Mar 9, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H C SchoutenP M Fayers
Feb 15, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C HosingI Khouri
Jun 11, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Tanya M WildesSteven M Devine
Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtNorbert Schmitz
Dec 15, 2010·Bone Marrow Transplantation·D J AndorskyL Pinter-Brown
Mar 1, 2012·American Journal of Hematology·Rebecca L ElstromUsama Gergis
Aug 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francesco d'AmoreHelle E Toldbod
Feb 5, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Dai ChiharaJunji Suzumiya
Sep 2, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Parastoo B DahiCraig S Sauter
Jun 30, 2015·British Journal of Haematology·Satyen H GohilKarl S Peggs
Oct 28, 2016·British Journal of Haematology·Christian W EskelundChristian H Geisler
Dec 4, 2016·Hematology·Andrew S Artz
Jan 10, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher J GibsonBenjamin L Ebert

❮ Previous
Next ❯

Citations

May 29, 2018·British Journal of Haematology·Christian Gisselbrecht, Eric Van Den Neste
Jul 4, 2019·Expert Review of Hematology·Catherine Tang, John Kuruvilla
Sep 5, 2020·Bone Marrow Transplantation·Robert PytlíkMarek Trněný
Apr 1, 2021·Nature Reviews. Nephrology·Frank BridouxNelson Leung

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

© 2022 Meta ULC. All rights reserved